Global uterine fibroids drug market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the increasing prevalence of uterine fibroids, rise in female population, growing screening; rising awareness and development in the healthcare expenditure and the government support for the research & development for new and better treatment have fueled the market growth.
The key market players in the global uterine fibroids drug market are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Teva Pharmaceutical Industries Ltd., Amgen Inc, Medtronic, Endo Pharmaceuticals Inc, Mylan N.V, Sun Pharmaceutical Industries Ltd, Hologic, Inc, Smith & Nephew, Merck & Co., Inc, ALLERGAN, Bayer AG, Koninklijke Philips N.V, IceCure Medical Ltd and others.
Ask For Complimentary Sample PDF| Request At https://databridgemarketresearch.com/request-a-sample/?dbmr=global-uterine-fibroids-drug-market
Reasons to Purchase this Report:
Current and future of global uterine fibroids drug market outlook in the developed and emerging markets.
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
Regions/Countries that are expected to witness the fastest growth rates during the forecast period.
The latest developments, market shares, and strategies that are employed by the major market players
Increasing prevalence of uterine fibroids is driving the market growth
Rising female population across the globe is driving the market growth.Growing screening across the world can also acts as a market driver
Rising awareness amongst people about the uterine fibroids and its treatment is also boosting the market growth
Side effects of treatment such as bleeding and infection during surgery can hamper the market growth
Low healthcare expenditure in developing regions also restricts the market growth
High cost-containment measures undertaken by governments along with the ongoing healthcare reforms.
Limited treatment options for uterine fibroids are restricting the market growth.
Table of Contents
2. Market Segmentation
3. Market Overview
4. Executive Summary
5. Premium Insights
6. Global, By Component
7. Product Type
Segmentation: Global Uterine Fibroids Drug Market
By Mechanism of Action
By Drugs Type
Magnetic Resonance Imaging (MRI)
By Route of Administration
Rest of Europe
Middle East & Africa
Key Developments in the Market
In July 2019, Myovant Sciences Ltd. reported positive primary outcome of the successful clinical trial for Relugolix combination therapy for the treatment of uterine fibroids. As, the phase III (LIBERTY 2) clinical trial hits the primary endpoint, as well as six secondary endpoints in women with uterine fibroids demonstrating the strong response rates in patients. Thus, the company seeks to file NDA to the U.S FDA
In November 2018, AbbVie Inc is developing Elagolix drug for the treatment of reducing heavy menstrual bleeding associated with uterine fibroids. The drug is currently undergoing phase lll clinical trial, an orally-administered, non-peptide, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist which inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. This drug has a potential as a future treatment for women with uterine fibroids
Inquiry For Customize Report With Discount at : https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-uterine-fibroids-drug-market
Global uterine fibroids drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of uterine fibroids drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
About Data Bridge Market Research
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Data Bridge Market Research